Novo Nordisk gets positive opinion on Tresiba for children in Europe

COPENHAGEN (Reuters) – Drug maker Novo Nordisk said the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of its diabetes drug Tresiba for the treatment of children and adolescents. An European Commission approval of the label expansion means physicians in the European Union will be able to prescribe Tresiba to children with type 1 and type 2 diabetes, Denmark’s Novo Nordisk said in a statement on Friday. …
Go to Source